When your patients want a non-hormonal therapy
for cyclic Heavy Menstrual Bleeding (HMB),
you can offer LYSTEDA
- LYSTEDA (tranexamic acid) tablets are the only non-hormonal treatment FDA approved for cyclic Heavy Menstrual Bleeding
- LYSTEDA is proven to significantly reduce menstrual blood loss. LYSTEDA reduced menstrual blood loss by 66 mL on average, a 38% overall reduction (vs 18 mL [12%] for placebo) †
Tranexamic acid has been used for decades to control excessive bleeding. The first US approval was in 1986 as an injectable for excessive dental bleeding. LYSTEDA is a unique tablet formulation of tranexamic acid specifically developed for excessive menstrual bleeding.
LYSTEDA has a unique MOA that acts downstream of coagulation
Click here for a short video of an expert in gynecology, Professor David F Archer, MD, discussing how LYSTEDA’s mechanism of action (MOA) works downstream from the coagulation cascade to lighten the patients’ heavy menstrual bleeding.
† A randomized, double-blind, placebo-controlled, 6-cycle clinical trial of 187 women. Dosing was two 650 mg tablets of LYSTEDA TID (3900 mg/day) or placebo for up to 5 days during menstruation. Heavy menstrual bleeding was defined as an average menstrual blood loss (MBL) ≥80 mL as assessed over 2 baseline menstrual cycles.
